References in periodicals archive ?
Ironwood Pharmaceuticals (NASDAQ: IRWD) is a GI-focused healthcare company focused on creating medicines that make a difference for patients living with GI diseases.
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases.
The Internet Retailer Web Design & Usability 2011 Conference (IRWD) is an annual event focused on helping e-retailers and web developers enhance the design of retail websites.
It plans to list its shares on the Nasdaq Global Market under the ticker "IRWD."
('Ironwood') (Nasdaq: IRWD), a GI-focused healthcare company, today announced that, in connection with its previously announced offering of 0.75% Convertible Senior Notes due 2024 (the '2024 Notes') and 1.50% Convertible Senior Notes due 2026 (the '2026 Notes' and, together with the 2024 Notes, the 'Notes'), the initial purchaser exercised in full its option to purchase $25 million aggregate principal amount of the 2024 Notes and $25 million aggregate principal amount of the 2026 Notes (the 'Additional Notes').
(NASDAQ: IRWD) plans to offer, subject to market and other conditions, USD 165m aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2024 and USD 165m aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2026, the company said.
Ironwood Pharmaceuticals (IRWD) announced the initiation of patient dosing in a Phase II clinical trial evaluating MD-7246 in patients with abdominal pain associated with irritable bowel syndrome with diarrhea.
According to the company, the property has been subdivided into three main components; 13 acres deeded to the City of Lake Forest for the construction of a new Civic Center, 27 acres retained by the IRWD to continue operation of the Baker Water Treatment Plant and the remaining 60 acres sold to Lennar Homes.
('Ironwood') (Nasdaq: IRWD), a GI-focused healthcare company, today announced the pricing of $175 million aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2024 (the '2024 Notes') and $175 million aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2026 (the '2026 Notes' and, together with the 2024 Notes, the 'Notes').
(NASDAQ: IRWD) and Irish pharmaceutical company Allergan plc (NYSE: AGN) have received positive topline data from a Phase IIIb clinical trial evaluating Linzess (linaclotide) 290 mcg on multiple abdominal symptoms in adult patients with IBS-C, the companies said.
AstraZeneca (AZN) announced that its partner Ironwood Pharmaceuticals (IRWD) has received marketing authorization from the National Medical Products Administration for Linzess in China for the treatment of adult patients with irritable bowel syndrome with constipation, or IBS-C.